Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
ACS Medicinal Chemistry Letters
|
March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology
Jeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Journal of Medicinal Chemistry
|
December 23, 2025
Optimization and Chemoproteomic Profiling of a Selective, Covalent Bfl-1-Targeting Cellular Tool
J Henry Blackwell, Simon C C Lucas, Giovanni Battocchio, et al.
ACS Medicinal Chemistry Letters
|
June 19, 2024
Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen
Simon C C Lucas, J Henry Blackwell, Ulf Börjesson, et al.
Journal of Medicinal Chemistry
|
December 6, 2024
Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors
Adeline Palisse, Tony Cheung, Aileen Blokhuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B Balachander, Steven W Criscione, Kate F Byth, et al.
ACS Medicinal Chemistry Letters
|
November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Nature Communications
|
December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
ACS Medicinal Chemistry Letters
|
March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology
Jeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Journal of Medicinal Chemistry
|
December 23, 2025
Optimization and Chemoproteomic Profiling of a Selective, Covalent Bfl-1-Targeting Cellular Tool
J Henry Blackwell, Simon C C Lucas, Giovanni Battocchio, et al.
ACS Medicinal Chemistry Letters
|
June 19, 2024
Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen
Simon C C Lucas, J Henry Blackwell, Ulf Börjesson, et al.
Journal of Medicinal Chemistry
|
December 6, 2024
Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors
Adeline Palisse, Tony Cheung, Aileen Blokhuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B Balachander, Steven W Criscione, Kate F Byth, et al.
ACS Medicinal Chemistry Letters
|
November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Nature Communications
|
December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Page
of 3